Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
about
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.Non-invasive diagnosis of liver fibrosis in chronic hepatitis CEconomic evaluation of screening programs for hepatitis C virus infection: evidence from literatureCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesCost-effectiveness of Telaprevir combination therapy for chronic hepatitis CCost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UKSofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisAsian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.Finasteride and methadone use and risk of advanced hepatitis C related liver disease.Diagnosis and Management of Hepatitis C Virus Infection.A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models.Tyrosine hydroxylase assay: a bioassay for aryl hydrocarbon receptor-active compounds based on tyrosine hydroxylase promoter activation.Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses.Checkmate to liver biopsy in chronic hepatitis C?Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence
P2860
Q26773187-5FCA5F1E-3613-4AF8-A8DC-E8680E924B57Q26865956-BF91EF86-235B-4E70-9B6E-7F8866CB1B6BQ26998567-CD243704-1517-42F9-9393-7D6AC9B84FE3Q28488762-0E8786AB-1A39-4D05-A2C3-1D2A00B3106FQ28540562-EA1F2897-D292-40C9-B486-4CEF9B4CB060Q30422586-ABBD9183-785B-4884-ABD4-C9636D142374Q33795154-430E71A9-2E60-45DF-A27C-1FE789AC5737Q35037688-EB1D5216-B51B-4CB0-B94F-6789E0B6A470Q36156172-CC0F4BF9-14E9-4155-9A51-BDE9A325BD94Q36406176-9BED1C2F-30A0-4557-9D42-0D4364A2AFADQ36997093-CF2BB9C1-D00D-4B5F-8B2E-BCFE65D23BEFQ38016312-3FDD6930-5A6A-4A61-9BA4-37E8E11459D9Q38327430-99C04B26-A035-4D89-8FC2-A5C3E8426FC0Q39039319-12984B38-4B75-4B22-82DD-0BE7D878A74AQ39384475-D560D462-A6FA-4CE3-8990-05A072AF91DAQ41350473-F1AEF079-505C-48DF-BD13-525858AABC14Q41678369-44078F8F-38CC-4912-BD0D-3389F2D6CFD7Q42048758-07E0B5A3-E091-471B-8D3A-4F2DEE4DBDDAQ42215056-45E55944-8270-4763-93B6-748D564E6FEFQ42227512-5E333384-527C-4C8D-A247-8D20BAFDA2F5Q42280296-08BB02DE-E8C1-458C-A283-8D8B041540B1Q55280669-7BD61A96-B3EA-4C28-8AB9-85E4C6382AE8Q57145115-1E0CD3E8-7889-45E8-BC41-09E947554EFC
P2860
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@ast
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@en
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@nl
type
label
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@ast
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@en
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@nl
prefLabel
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@ast
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@en
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@nl
P2093
P2860
P1433
P1476
Cost effectiveness of fibrosis ...... chronic hepatitis C patients.
@en
P2093
Jeremy D Goldhaber-Fiebert
Michaël Schwarzinger
P2860
P304
P356
10.1371/JOURNAL.PONE.0026783
P407
P577
2011-12-02T00:00:00Z